Market capitalization | KRW5.93t |
Enterprise Value | KRW5.88t |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 14.40 |
P/S ratio (TTM) P/S ratio | 14.53 |
P/B ratio (TTM) P/B ratio | 19.48 |
Sales growth (TTM) Sales growth | 53.52% |
Turnover (TTM) Turnover | KRW408.08b |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
15 Analysts have issued a SK Biopharmaceuticals forecast:
15 Analysts have issued a SK Biopharmaceuticals forecast:
Dec '23 |
+/-
%
|
||
Turnover | 354,892 354,892 |
44%
44%
|
|
Gross income | 308,374 308,374 |
57%
57%
|
|
EBITDA | -22,777 -22,777 |
81%
81%
|
EBIT (operating result) EBIT | -38,094 -38,094 |
71%
71%
|
Net profit | -32,883 -32,883 |
76%
76%
|
Figures in millions KRW.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
SK Biopharmaceuticals Co., Ltd. engages in the research and development of new drugs and antibiotics. It mainly develops new drugs for central nervous system disorders, and brain tumors. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea.
Head office | South Korea |
CEO | Dong-Hoon Lee |
Employees | 273 |
Founded | 1993 |
Website | www.skbp.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.